Pandemic Flu Home MedKits Headed To NDAC/Antiviral Joint Panel
This article was originally published in The Tan Sheet
Executive Summary
FDA's next advisory panel meeting on nonprescription drugs will consider the pre-deployment of antiviral influenza drug "MedKits" in preparation for a possible pandemic
You may also be interested in...
OTC Anthrax MedKit Development Relies On Incremental Approach
HHS’ Biomedical Advanced Research and Development Authority will ask FDA and its advisors about the feasibility of an OTC antibiotic MedKit for anthrax treatment at an advisory committee meeting.
OTC Anthrax MedKit Development Relies On Incremental Approach
HHS’ Biomedical Advanced Research and Development Authority will ask FDA and its advisors about the feasibility of an OTC antibiotic MedKit for anthrax treatment at an advisory committee meeting.
FDA Panel To Influenza Home MedKit Sponsors: Get Real
Roche begins label comprehension studies this month to support development of aTamiflu home MedKit for the treatment or prophylaxis of pandemic influenza virus, under an initiative driven by the Department of Health and Human Services